BioSpace News Archive

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022.

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. EST on Friday, August 12, 2022.

Catalent today announced that it will release financial results for the fourth quarter of fiscal year 2022 ended June 30, 2022, before the market open on Monday, August 29, 2022.

Quoin Pharmaceuticals Ltd. announced the pricing of its “reasonable best efforts” public offering of 11,050,000,000 ordinary shares represented by 2,210,000 American Depositary Shares at a purchase price of $5.00 per ADS and pre-funded warrants to purchase 5,750,000,000 ordinary shares represented by 1,150,000 American Depositary Shares at a per pre-funded warrant price of $4.9999 for an aggregate gross proceeds of $16.8 million.

Forecast to 2030,’ thoroughly examines the ARDS Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Heavy Metal Poisoning industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Monkeypox Treatment industry to provide essential data & information for the targeted readers.

The global closed system transfer devices (CSTD) market is expected to expand at a CAGR of 11% during the assessment period.

According to Report study, the global echocardiography market is projected to cross a revenue of US$ 2.2 Bn by 2030.

The newborn screening market is expected to advance at a robust CAGR of 11% during the forecast period.